All In MedTech

Device Trial Radar · NCT04221503

Niraparib/TTFields in GBM

A Phase II Study Evaluating the Efficacy and Safety of Niraparib and Tumor-Treating Fields in Recurrent Glioblastoma

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 30, 2019

Primary completion

Jan 2026

Study completion Jan 2026

Sponsor

Lead sponsor
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tesaro, Inc.; NovoCure Ltd.
First posted
Jan 9, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).

Conditions

  • Glioblastoma
  • Recurrent Glioblastoma
  • GBM

Interventions

  • NiraparibDrug

    Niraparib (\[3S\]-3-\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.

  • OptuneDevice

    Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields ("TTFields") within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells.

  • Planned surgical resectionProcedure

    Surgery of supratentorial glioblastoma (GBM).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease control, defined as achievement of either CR, PR, or SD, as defined by modified Response Assessment in Neuro-Oncology (mRANO) criteria.Time frame: When termination of the study or 5 years after removal from protocol therapy, whichever occurs first.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.